The deubiquitinase (DUB) USP13 promotes Mcl-1 stabilisation in cervical cancer
Open Access
- 24 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 40 (11), 2112-2129
- https://doi.org/10.1038/s41388-021-01679-8
Abstract
Protein ubiquitination is a critical regulator of cellular homeostasis. Aberrations in the addition or removal of ubiquitin can result in the development of cancer and key components of the ubiquitination machinery serve as oncogenes or tumour suppressors. An emerging target in the development of cancer therapeutics are the deubiquitinase (DUB) enzymes that remove ubiquitin from protein substrates. Whether this class of enzyme plays a role in cervical cancer has not been fully explored. By interrogating the cervical cancer data from the TCGA consortium, we noted that the DUB USP13 is amplified in ~15% of cervical cancer cases. We confirmed that USP13 expression was increased in cervical cancer cell lines, cytology samples from patients with cervical disease and in cervical cancer tissue. Depletion of USP13 inhibited cervical cancer cell proliferation. Mechanistically, USP13 bound to, deubiquitinated and stabilised Mcl-1, a pivotal member of the anti-apoptotic BCL-2 family. Furthermore, reduced Mcl-1 expression partially contributed to the observed proliferative defect in USP13 depleted cells. Importantly, the expression of USP13 and Mcl-1 proteins correlated in cervical cancer tissue. Finally, we demonstrated that depletion of USP13 expression or inhibition of USP13 enzymatic activity increased the sensitivity of cervical cancer cells to the BH3 mimetic inhibitor ABT-263. Together, our data demonstrates that USP13 is a potential oncogene in cervical cancer that functions to stabilise the pro-survival protein Mcl-1, offering a potential therapeutic target for these cancers.Keywords
Funding Information
- RCUK | Medical Research Council (MR/ K012665)
- MOH | National Medical Research Council (MR/S001697/1)
- RCUK | Biotechnology and Biological Sciences Research Council (BB/M011151/1)
- RCUK | MRC | Medical Research Foundation (MR/S001697/1)
This publication has 85 references indexed in Scilit:
- Human Papillomavirus (HPV) Upregulates the Cellular Deubiquitinase UCHL1 to Suppress the Keratinocyte's Innate Immune ResponsePLoS Pathogens, 2013
- The HPV16 E6 Oncoprotein Causes Prolonged Receptor Protein Tyrosine Kinase Signaling and Enhances Internalization of Phosphorylated Receptor SpeciesPLoS Pathogens, 2013
- Mcl-1 Phosphorylation Defines ABT-737 Resistance That Can Be Overcome by Increased NOXA Expression in Leukemic B cellsCancer Research, 2012
- Beclin1 Controls the Levels of p53 by Regulating the Deubiquitination Activity of USP10 and USP13Cell, 2011
- The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myelomaPublished by American Society of Hematology ,2010
- USP10 Regulates p53 Localization and Stability by Deubiquitinating p53Cell, 2010
- Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized TrialsJournal of Clinical Oncology, 2008
- Inactivation of the CYLD Deubiquitinase by HPV E6 Mediates Hypoxia-Induced NF-κB ActivationCancer Cell, 2008
- Human Papillomavirus Type 16 E7 Oncoprotein Associates with the Cullin 2 Ubiquitin Ligase Complex, Which Contributes to Degradation of the Retinoblastoma Tumor SuppressorJournal of Virology, 2007
- Papillomaviruses and cancer: from basic studies to clinical applicationNature Reviews Cancer, 2002